UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/541,947	12/12/2005	James N. Petitte	297/204 PCT/US	1436
JENKINS, WILSON, TAYLOR & HUNT, P. A. SUITE 1200, UNIVERSITY TOWER 3100 TOWER BOULEVARD DURHAM, NC 27707			EXAMINER	
			WILSON, MICHAEL C	
			ART UNIT	PAPER NUMBER
·			1632	
			- · · · · · · · · · · · · · · · · · · ·	
		,	MAIL DATE	DELIVERY MODE
			05/16/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

•	Application No.	Applicant(s)				
Office Action Comments	10/541,947	PETITTE ET AL.				
Office Action Summary	Examiner	Art Unit				
	Michael C. Wilson	1632				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DATE of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period we failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION (6(a). In no event, however, may a reply be time of the computation to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on	_					
· <u> </u>	☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4) Claim(s) <u>1-57</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6)☐ Claim(s) is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) 1-57 are subject to restriction and/or e	election requirement.					
Application Papers	•					
9) The specification is objected to by the Examine	r. ·					
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.						
Applicant may not request that any objection to the	drawing(s) be held in abeyance. See	e 37 CFR 1.85(a).				
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Ex	aminer. Note the attached Office	Action or form PTO-152.				
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) ☐ All b) ☐ Some * c) ☐ None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.						
•						
Attachment(s)		•				
1) Notice of References Cited (PTO-892)	4) Interview Summary	·				
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08)	Paper No(s)/Mail Da 5) Notice of Informal P					
Paper No(s)/Mail Date	6) Other:					

Art Unit: 1632

DETAILED ACTION

Claims 1-57 are pending.

Specification

Each of Figures 1-3 should be described in a separate paragraph on pg 9.

This application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the following reasons: the amino acid sequence on pg 13, lines 5-6, require a SEQ ID NO. Applicants must file a "Sequence Listing" accompanied by directions to enter the listing into the specification as an amendment. Applicant also must provide statements regarding sameness and new matter with regards to the CRF and the "Sequence Listing." Failure to fully comply with the sequence rules in response to the instant office action will be considered non-responsive.

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-12, drawn to a method of increasing the number of PGCs in an avian embryo.

Group II, claim(s) 1-12, drawn to a method of decreasing the number of PGCs in an avian embryo.

Group III, claim(s) 13-15, 17-26, drawn to producing a chimeric avian using donor PGCs from the same avian species as the recipient embryo.

Art Unit: 1632

Group IV, claim(s) 13, 14, 16-26, drawn to producing a chimeric avian using donor PGCs from a different avian species as the recipient embryo.

Group V, claim(s) 27-29, 31-37, drawn to increasing the proportion of male birds in a plurality of bird eggs using donor PGCs from the same avian species as the recipient embryo.

Group VI, claim(s) 27, 28 and 30-37, drawn to increasing the proportion of male birds in a plurality of bird eggs using donor PGCs from a different avian species than the recipient embryo.

Group VII, claims 38-41, 43-47, drawn to producing avian gametes from a second avian species in a first avian species wherein the first and second avian species are the same.

Group VIII, claims 38-40, 42-47, drawn to producing avian gametes from a second avian species in a first avian species wherein the first and second avian species are the same.

Groups IX, claims 48-51, 53-57, drawn to a method of enhancing germ line transmission of a nucleic acid molecule in a bird using donor PGCs that are from the same avian species as the recipient bird.

Groups X, claims 48-50, 52-57, drawn to a method of enhancing germ line transmission of a nucleic acid molecule in a bird using donor PGCs that are from the same avian species as the recipient bird.

The inventions listed as Groups I-X do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The groups do not share the same technical feature. Increasing and decreasing the number of PGCs in an avian embryo are not the same technical feature. Modulating the number of PGCs in an avian embryo (claim 1) is not the same technical feature as producing a chimeric avian (claim 13), increasing the number of male birds (claim 27), producing avian gametes from a second avian species in a first avian species (claim 38) or enhancing germline transmission of a nucleic acid sequence in a bird (claim 48).

Art Unit: 1632

This application contains claims directed to the following patentably distinct species: SSEA-1, VASA, EMA-1, germ cell-less, dead end, nanos, stella, fragilis, and DAZL. The species are independent or distinct because they have different structures and functions and are not exclusive markers of avian PGCs.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, all the claims are generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species.

MPEP § 809.02(a).

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

Art Unit: 1632

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Inquiry concerning this communication or earlier communications from the examiner should be directed to Michael C. Wilson who can normally be reached at the office on Monday, Tuesday, Thursday and Friday from 9:30 am to 6:00 pm at 571-272-0738.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within

Art Unit: 1632

5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

If attempts to reach the examiner are unsuccessful, the examiner's supervisor, Peter Paras, can be reached on 571-272-4517.

The official fax number for this Group is (571) 273-8300.

Michael C. Wilson

MICHAEL WILSON PRIMARY EXAMINER